Lichen Planus

Researchers are evaluating the use of a non-ablative 1470 nm laser to treat androgenetic alopecia and scarring alopecia in adults. This pilot study is open-label, baseline-controlled, and conducted at a single center. The study includes participants with biopsy-proven alopecia who have experienced stable hair loss for at least six months. The goal is to explore the laser's effects on hair loss improvement, as it has not yet been tested for these conditions despite FDA clearance for dermatologic use. Participants will be divided into two groups, each with five people: one group for androgenetic alopecia and one for scarring alopecia. Each subject may receive up to three laser treatments targeting multiple areas of the scalp. Treatments last about 10 to 15 minutes and follow a protocol that includes topical anesthetic and antiseptic cleaning before the laser application. Post-treatment care includes applying a topical steroid cream. Follow-up visits are scheduled at months 6, 9, 12, and 15 to monitor progress. Throughout the study, researchers will conduct clinical assessments including standardized photography and hair density measurements using the Canfield HairMetrix® device. Participants will complete questionnaires to report pain levels, hair growth self-assessments, and any adverse events. Primary outcomes include live and photographic assessments of hair loss, hair density, and hair counts at multiple timepoints up to month 15. Subject satisfaction will also be tracked. The study duration allows careful monitoring of changes and safety over more than a year.

This research aims to evaluate how full-arch implant-supported prostheses affect lip support in patients undergoing complex dental rehabilitation. The study focuses on how different clinical and laboratory decisions between diagnosis and prosthesis delivery may influence the prosthetic design and the patient's facial profile. Advanced 3D facial scanning and superimposition techniques allow precise measurement of vertical occlusion and lip support. Participants will undergo removal of their full-arch implant-supported prostheses, with digital facial images captured before and after this procedure using a facial scanner. This observational study leverages modern digital technology to measure changes objectively and does not involve experimental treatments. During the study, researchers will assess changes in the volume around the mouth area, distances between the lips and esthetic lines on the facial profile, and angles related to the nose and lips. These measurements occur on the same day as the prosthesis removal. The study helps improve understanding of facial changes related to dental prostheses and involves participants collaborating with the research protocol through imaging and clinical assessments.

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 2/3 randomized, double-blind, placebo-controlled study aims to understand how well this drug works compared to a placebo in improving symptoms of this condition. The trial is sponsored by Priovant Therapeutics, Inc. and focuses on finding treatments that may help reduce disease activity and symptoms. Participants will be randomly assigned to receive either oral brepocitinib or a placebo. The study will monitor their progress over 24 weeks, measuring changes using the Investigator's Global Assessment (IGA) score and symptom rating scales. The trial includes a treatment period where participants take the oral medication and are regularly assessed for response and safety. Throughout the study, participants will have clinical evaluations to track their scalp condition and symptom changes. The main outcome measured is the proportion of participants achieving a significant improvement in IGA score by week 24. Secondary outcomes include changes in symptom severity. Safety will be closely monitored, and the total duration of participation will cover the treatment and follow-up periods up to week 24.

Researchers are evaluating camoteskimab, a drug being studied in adults with moderate-to-severe atopic dermatitis. This phase 2b study is multicenter, randomized, double-blind, and placebo-controlled, aiming to assess the drug's effects compared to placebo. Participants include those who have not been treated before and those who have had an inadequate response to previous biologic therapies. The study has two parts: Part 1 is a 24-week period where participants are randomly assigned to one of four groups receiving one of three doses of camoteskimab or a placebo, all given by subcutaneous injection. In Part 2, an extension period, all participants will receive camoteskimab. This design allows researchers to compare the drug doses with placebo initially and then provide treatment to all participants. Participants will be involved for at least 24 weeks in the placebo-controlled phase and beyond during the extension. They will undergo assessments including the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), and peak itch ratings. Researchers will measure changes in eczema severity, itch intensity, and skin condition over time. Safety and adherence will be monitored throughout the study period to evaluate the drug's effects and tolerability.

This research aims to evaluate the accuracy of the Belle.ai software in diagnosing common dermatologic diseases across different skin tones. The software uses deep learning technology to analyze clinical images of skin conditions and provides a differential diagnosis from a database of over 2,000 skin conditions based on more than 500,000 images. The study will determine how well the AI-generated diagnoses match those of dermatology experts. Participants who consent will have three images taken of their skin condition using the Belle.ai software. These images will be de-identified and uploaded into the system, where the software will generate a single list of possible diagnoses. Dermatology experts will then review the cases to compare their diagnoses with the AI results. The study will be conducted at dermatology clinics within the Advocate Health system. During the study, images will be captured and uploaded securely without any personal identifiers. The Dermatologic Review Committee will assess the concordance between the AI's primary diagnosis and expert opinions, aiming for greater than 80% agreement. Participants will not need to complete any additional forms, and their involvement primarily involves image capture during their clinic visit. The main outcome measured is the agreement between AI and physician diagnoses on the day of image capture.

Researchers are evaluating the safety and effectiveness of baricitinib for treating severe or very severe alopecia areata, a condition causing hair loss, in children aged 6 to less than 18 years. This Phase 3 clinical trial aims to determine how well baricitinib works in this young population, with careful monitoring of outcomes related to hair regrowth and patient well-being. Participants will be randomly assigned to one of three groups: a high dose of baricitinib, a low dose of baricitinib, or a placebo. The study includes four periods: a 5-week screening phase to determine eligibility, a 36-week double-blind treatment period where participants receive their assigned treatment, an approximately 2-year long-term extension to observe longer-term effects, and a 4-week follow-up after treatment ends. Some participants may continue to receive treatment after the extension for up to 180 weeks. During the trial, children will undergo regular assessments including the Severity of Alopecia Tool (SALT) score to measure hair loss, patient-reported outcomes on scalp hair, eyebrow, and eyelash hair, as well as evaluations of anxiety, depression, and quality of life. Blood tests will monitor drug levels and immune response. Participants will be closely followed throughout the study periods to track changes and ensure safety, with the total participation lasting over two years depending on extension eligibility.

Researchers are evaluating noninvasive imaging methods to study the appearance of skin and mucosal lesions to improve diagnostic accuracy before a biopsy is needed and to help guide treatment planning. This study involves creating an Image Repository to store these images for clinical practice, teaching, training, and future research. It uses a high-resolution Optical Coherence Tomography (OCT) device called ApolloVueae S100 Image System that provides detailed cross-sectional and en-face images with cellular information. Participants with muco-cutaneous lesions, including normal skin, benign lesions, or neoplastic conditions, identified during routine clinical care will undergo various non-invasive imaging tests. These include dermoscopic imaging, 3-dimensional total body photography, confocal microscopy, OCT imaging, ultrasound, hyperspectral imaging, electrical impedance spectroscopy, and patient self-imaging using mobile phone technology with dermatoscope attachments. Images will be collected of untreated and treated lesions over a period of 7 years. Participants will have their lesions imaged using these non-invasive tools, with images collected and stored in the Image Repository. Assessments include capturing detailed images using specialized devices to evaluate lesion morphology, depth, vascular features, and biochemical information. Researchers will monitor the imaging data to support clinical decisions, teaching, and future research. Participation may involve multiple imaging sessions over time, and safety monitoring includes ensuring no allergic reactions to imaging materials. The study welcomes healthy volunteers and all ages, with informed consent or parental consent and patient assent as applicable.

Researchers are conducting a first-in-human study to evaluate BG-A3004, a biological treatment being studied for safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics. The trial includes healthy participants and patients with immune-mediated skin diseases such as alopecia areata, cutaneous lichen planus, and nonsegmental vitiligo. This phase 1, randomized, double-blind, placebo-controlled study aims to better understand how BG-A3004 behaves in the body and its effects in these groups over about three years. The study has two parts: Part A involves healthy participants receiving a single subcutaneous dose of BG-A3004 or placebo, with sequential dose escalation. Part B includes patients with immune-mediated skin diseases receiving multiple subcutaneous doses of BG-A3004 or placebo across increasing dose levels. Part A participants get one dose, while Part B participants receive four doses. Safety follow-up continues for 168 days after the last dose in both parts. Participants will undergo medical evaluations, laboratory tests, and cardiac monitoring before and during the study. Researchers will monitor adverse events and serious adverse events for up to 24 weeks in Part A and 36 weeks in Part B. They will also measure drug concentration, half-life, and antibody formation against BG-A3004. The total study duration is approximately three years, including dosing, safety follow-up, and assessments to understand how the drug interacts with the body and its safety profile.

Researchers are evaluating the safety and effectiveness of Oleogel-S10 gel in treating skin wounds caused by two inherited forms of epidermolysis bullosa (EB), called junctional EB (JEB) and dystrophic EB (DEB), specifically in the Japanese population. This trial aims to find out if Oleogel-S10 gel can close wounds or reduce their size within 45 days, assess its safety, and measure how much of the gel enters the bloodstream. Both children and adults are invited to join this study. Participants apply Oleogel-S10 gel to their EB wound dressings at least once every four days for 45 days in Part 1 of the study. They visit the clinic every two weeks for checkups and tests during this period. Those who complete Part 1 may choose to continue in Part 2, where they keep receiving Oleogel-S10 gel until it becomes available for purchase in Japan or until the study is stopped by the company. During the study, participants will have regular clinic visits for examinations and tests to monitor wound healing, safety, and drug exposure. Researchers will evaluate the gel's effect on wounds up to 45 days in Part 1 and up to 90 days in Part 2. Safety and tolerability will be assessed throughout the study, which may continue until 2029. Participants will be supervised closely and asked to follow all study instructions and procedures.

Researchers are evaluating real-world treatment patterns and clinical outcomes in patients aged 12 years and older with moderate-to-severe atopic dermatitis who are receiving abrocitinib. The study aims to describe patient demographics and baseline characteristics over a 12-month observation period to better understand how abrocitinib is used in usual clinical practice conditions. Participants will be newly prescribed abrocitinib as decided by their physician during routine care. The study does not involve experimental treatments but observes how abrocitinib is used and its effects in everyday settings. There are no comparator groups or placebo treatments since this is an observational study. During the 12-month observation, researchers will track improvements in eczema severity using measures like the Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), and patient-reported outcomes such as the Peak Pruritus Numerical Rating Scale (PP-NRS). Data on treatment duration, quality of life, and symptom changes will also be collected. Patients' progress will be monitored at multiple time points including weeks 2, 4, 12, 16, 24, and 52.